CD40LG and neoplasm: As presented, compared with the control group, all sera treatments could apparently attenuate the S180 cell viabilities (p < 0.05), indicating that the antibodies in sera could directly inhibit the proliferation of tumor cells, which might be mainly induced by the IgM antibody according to variation trends of the above results.